Literature DB >> 31260114

Liver neoplasms in methylmalonic aciduria: An emerging complication.

Patrick Forny1, Michel Hochuli2, Yusof Rahman3, Maesha Deheragoda4, Achim Weber5,6, Julien Baruteau1,7, Stephanie Grunewald1.   

Abstract

Methylmalonic aciduria (MMA) is an inherited metabolic disease caused by methylmalonyl-CoA mutase deficiency. Early-onset disease usually presents with a neonatal acute metabolic acidosis, rapidly causing lethargy, coma, and death if untreated. Late-onset patients have a better prognosis but develop common long-term complications, including neurological deterioration, chronic kidney disease, pancreatitis, optic neuropathy, and chronic liver disease. Of note, oncogenesis has been reported anecdotally in organic acidurias. Here, we present three novel and two previously published cases of MMA patients who developed malignant liver neoplasms. All five patients were affected by a severe, early-onset form of isolated MMA (4 mut0 , 1 cblB subtype). Different types of liver neoplasms, that is, hepatoblastoma and hepatocellular carcinoma, were diagnosed at ages ranging from infancy to adulthood. We discuss pathophysiological hypotheses involved in MMA-related oncogenesis such as mitochondrial dysfunction, impairment of tricarboxylic acid cycle, oxidative stress, and effects of oncometabolites. Based on the intriguing occurrence of liver abnormalities, including neoplasms, we recommend close biochemical and imaging monitoring of liver disease in routine follow-up of MMA patients.
© 2019 SSIEM.

Entities:  

Keywords:  hepatoblastoma; hepatocellular carcinoma; liver; methylmalonic aciduria; mitochondrial dysfunction; oncogenesis; oxidative stress

Year:  2019        PMID: 31260114     DOI: 10.1002/jimd.12143

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  7 in total

Review 1.  Toxic Metabolites and Inborn Errors of Amino Acid Metabolism: What One Informs about the Other.

Authors:  Namgyu Lee; Dohoon Kim
Journal:  Metabolites       Date:  2022-06-08

2.  ESR1 Regulates the Obesity- and Metabolism-Differential Gene MMAA to Inhibit the Occurrence and Development of Hepatocellular Carcinoma.

Authors:  Yiyin Zhang; Jiaxi Cheng; Cheng Zhong; Qiming Xia; Yirun Li; Peng Chen; Xiaoxiao Fan; Qijiang Mao; Hui Lin; Defei Hong
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

Review 3.  Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.

Authors:  Teodoro Jerves; Nenad Blau; Carlos R Ferreira
Journal:  Mol Genet Metab       Date:  2022-03-28       Impact factor: 4.204

4.  Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision.

Authors:  Patrick Forny; Friederike Hörster; Diana Ballhausen; Anupam Chakrapani; Kimberly A Chapman; Carlo Dionisi-Vici; Marjorie Dixon; Sarah C Grünert; Stephanie Grunewald; Goknur Haliloglu; Michel Hochuli; Tomas Honzik; Daniela Karall; Diego Martinelli; Femke Molema; Jörn Oliver Sass; Sabine Scholl-Bürgi; Galit Tal; Monique Williams; Martina Huemer; Matthias R Baumgartner
Journal:  J Inherit Metab Dis       Date:  2021-03-09       Impact factor: 4.750

Review 5.  Metabolomics and the Multi-Omics View of Cancer.

Authors:  David Wishart
Journal:  Metabolites       Date:  2022-02-07

6.  Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia.

Authors:  Shengwen Zhang; Amy Bastille; Susana Gordo; Nikhil Ramesh; Jenisha Vora; Elizabeth McCarthy; Xiaohan Zhang; Dylan Frank; Chih-Wei Ko; Carmen Wu; Noel Walsh; Shreya Amarwani; Jing Liao; Qiang Xiong; Lauren Drouin; Matthias Hebben; Kyle Chiang; B Nelson Chau
Journal:  PLoS One       Date:  2022-09-20       Impact factor: 3.752

Review 7.  Mitochondrial disease, mitophagy, and cellular distress in methylmalonic acidemia.

Authors:  Alessandro Luciani; D Sean Froese; Matthew C S Denley; Larissa P Govers; Vincenzo Sorrentino
Journal:  Cell Mol Life Sci       Date:  2021-09-15       Impact factor: 9.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.